Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jerry Wolinsky

Neurology Houston, TX Medical Doctor

NPI 1578599007 CMS profile 25542

6410 Fannin St, 1014, Houston, TX 77030

Open in the dashboard

General payments

$165,360

138 records reported · program years 2019–2025

Research payments

$103,950

Paid to them · 71 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jerry Wolinsky of Houston, TX is reported in the CMS Open Payments database as having received $165,360 across 138 general payments and $103,950 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $345 1
2025 Research $21,515 6
2024 General $109 1
2024 Research $4,986 4
2023 General $4,988 4
2023 Research $4,573 3
2022 General $4,665 5
2022 Research $4,661 4
2021 General $9,035 6
2021 Research $20,262 18
2020 General $14,622 10
2020 Research $34,714 30
2019 General $131,596 111
2019 Research $13,240 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jerry Wolinsky
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Jerry Wolinsky were reported at $345. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Jerry Wolinsky Neurology median Middle half National median
2019 $131,596 $474 $118–$2,177 $163
2020 $14,622 $367 $82–$2,309 $114
2021 $9,035 $438 $104–$2,547 $132
2022 $4,665 $442 $103–$2,388 $149
2023 $4,988 $464 $119–$2,312 $160
2024 $109 $468 $119–$2,323 $164
2025 $345 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $54,261 55 payments
  2. Novartis Pharma AG $41,340 27 payments
  3. Sanofi-Aventis U.S. LLC $18,809 8 payments
  4. Genentech, Inc. $15,872 17 payments
  5. EMD Serono, Inc. $13,383 10 payments
  6. Greenwich Biosciences, Inc. $6,806 6 payments
  7. GW Pharma Limited $6,602 5 payments
  8. Hexal AG $4,225 2 payments
  9. Roche Products Limited $2,100 2 payments
  10. EMD Serono Research & Development Institute, Inc. $1,720 2 payments
  11. Other $241 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $79,745 38 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $43,667 51 payments
  3. Travel and Lodging $40,541 29 payments
  4. Food and Beverage $1,407 20 payments
Products named General payments · program years 2019–2025
  1. OCREVUS $69,895 67 payments
  2. OMB157G_ARZERRA_HEMATOLOGY $41,999 27 payments
  3. AUBAGIO Multiple Sclerosis $17,829 6 payments
  4. Epidiolex $6,806 6 payments
  5. AUBAGIO Neurology $980 2 payments
  6. GILENYA $99 2 payments
  7. FTY720_GILENYA_NEUROSCIENCE $75 2 payments
  8. FTD_GILENYA_NEUROSCIENCE $30 2 payments
  9. BRIUMVI $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $81,558 59 payments
  2. Novartis Pharma AG $15,600 3 payments
  3. Genentech, Inc. $2,700 2 payments
  4. EMD Serono, Inc. $2,479 2 payments
  5. Sanofi-Aventis U.S. LLC $1,164 3 payments
  6. Genzyme Corporation $449 2 payments

Records

209 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record